Repaglinide is a medication used to treat type 2 diabetes by reducing blood sugar levels. However, the drug can contain impurities which may affect its efficacy and safety. These impurities may arise during the manufacturing process or due to degradation of the drug over time. Regulatory authorities set limits on the amount of impurities allowed in Repaglinide to ensure its quality and safety. Analytical methods are used to detect and quantify these impurities, and manufacturers are required to monitor and control them to ensure the drug's quality and safety.
